Europe Cardiac Sarcoidosis Market – Industry Trends and Forecast to 2030

Análisis y tamaño del mercado de sarcoidosis cardíaca en Europa

La sarcoidosis es una enfermedad inflamatoria multisistémica de etiología desconocida. La sarcoidosis cardíaca se diagnostica en aproximadamente el 2-5% de los pacientes con otra sarcoidosis sistémica; sin embargo, las autopsias han revelado que la sarcoidosis cardíaca puede alcanzar el 20-30% en los Estados Unidos. Los afroamericanos tienen una prevalencia de sarcoidosis 3,8 veces mayor que los caucásicos en los Estados Unidos y Europa. La prevalencia de sarcoidosis cardíaca en pacientes japoneses puede llegar al 58% y es la causa de muerte en el 85% de los pacientes con sarcoidosis en Japón. La sarcoidosis cardiovascular tiene un mal pronóstico y los pacientes pueden deteriorarse rápidamente.

Data Bridge Market Research analiza que el mercado de sarcoidosis cardíaca, que fue de USD 22669,05 millones en 2022, se espera que alcance los USD 65120,61 millones para 2030, a una CAGR del 14,1% durante el período de pronóstico de 2023 a 2030. Además de los conocimientos sobre escenarios de mercado como valor de mercado, tasa de crecimiento, segmentación, cobertura geográfica y actores principales, los informes de mercado seleccionados por Data Bridge Market Research también incluyen análisis de expertos en profundidad, epidemiología de pacientes, análisis de canalización, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de sarcoidosis cardíaca en Europa      

Definición de mercado

La sarcoidosis cardíaca es una enfermedad inflamatoria poco frecuente en la que las células inmunitarias forman granulomas en diversas zonas del corazón, lo que provoca problemas que van desde arritmias hasta insuficiencia cardíaca. Las causas de la sarcoidosis cardíaca se desconocen en este momento. Una reacción exagerada del sistema inmunitario puede provocar la enfermedad a un agente infeccioso (como bacterias o virus), una sustancia química o un alérgeno.

Dinámica del mercado de la sarcoidosis cardíaca en Europa

Conductores

• Aumento de las enfermedades cardiovasculares

También se observa un aumento de la prevalencia de la obesidad entre adultos y jóvenes, que es una de las principales causas de las enfermedades cardiovasculares, lo que impulsa el crecimiento del mercado. A medida que aumenta la prevalencia de las enfermedades cardiovasculares, también aumenta la conciencia pública sobre la salud, lo que impulsa a las personas a buscar métodos de diagnóstico y tratamiento más sencillos y accesibles, como dispositivos de monitorización cardíaca fáciles de usar. Como resultado, se espera que el mercado crezca rápidamente debido a un aumento de las enfermedades cardiovasculares durante el período de pronóstico.

• Mayor demanda de medicamentos y diagnóstico para la sarcoidosis cardíaca

El tratamiento con corticosteroides puede retardar la progresión de la enfermedad cardíaca y mejorar la supervivencia, pero no parece reducir la frecuencia de las arritmias ventriculares. 16 Se desconoce el mecanismo de acción de los esteroides en la sarcoidosis cardíaca, pero se cree que estos agentes pueden retardar la progresión de la inflamación y la fibrosis al restablecer un equilibrio TH1/TH2 normal. w32 Al principio, se prescriben comúnmente dosis de prednisona de 60-80 mg por día. En un estudio, se encontró que una dosis inicial de 30 mg/día era adecuada para mejorar el pronóstico. Estos son los factores seguros para mejorar el diagnóstico de sarcoidosis cardíaca.

Oportunidades

• Desarrollo de nuevos y avanzados fármacos contra la sarcoidosis cardíaca

Gammagrafía con galio67 La gammagrafía con galio67 también se utiliza para diagnosticar la afectación miocárdica en la sarcoidosis. El galio67 se acumula solo en áreas de inflamación activa, por lo que la prueba solo es positiva cuando la enfermedad está activa. Okayama y sus colegas informaron que cuando el talio mostró defectos miocárdicos, la captación cardíaca de galio no agregó más información diagnóstica, pero fue predictiva de la eficacia del tratamiento con corticosteroides.

La tomografía computarizada por emisión monofotónica (SPECT) con galio suele dificultar la visualización de la captación anormal de nucleidos en el miocardio, debido a la incapacidad de distinguir la captación de galio en otros órganos de la captación en el miocardio. Nakazawa y sus colegas informaron recientemente que la SPECT dual con galio67 y tecnecio99m puede mejorar significativamente la precisión y la resolución espacial de la SPECT con galio67 en el diagnóstico de la sarcoidosis cardíaca.

Restricciones/Desafíos

• Complicaciones del tratamiento antiarrítmico

Antiarrhythmic therapy and blockers are frequently required in the treatment of sarcoid heart disease. There have been no prospective studies evaluating the use of these agents in cardiac sarcoidosis patients. Blockers may increase the risk of heart block, and amiodarone may worsen restrictive lung disease in sarcoidosis. As a result, the doctor must carefully weigh the benefits and risks of prescribing these medications.

This cardiac sarcoidosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac sarcoidosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In April 2020, Mallinckrodt sponsored an awareness programme launched by the American Lung Association (ALA) and the Foundation for Sarcoidosis Research (FSR) to empower sarcoidosis patients to fight against such a chronic disease and follow some measures to protect themselves from cardiac sarcoidosis. The launch of this awareness campaign aided the company in raising its public profile.
• In July 2019, Hikma Pharmaceuticals PLC and Civica entered into a five-year agreement to reduce the generic drug shortage in the United States. Most drugs used to treat cardiac sarcoidosis, including methotrexate, are available as generic drugs. This agreement enabled the company to maintain a continuous drug supply, allowing it to invest significantly in expanding its manufacturing capabilities.

Europe Cardiac Sarcoidosis Market Scope

The cardiac sarcoidosis market is segmented on the basis of treatment, drugs type, inhibitors, route of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Diagnosis
• CT Scan
• PET
• ECG
• Others
• Drugs
• Methotrexate
• Corticosteroids
• Immunosuppressant Drugs
• Mycophenolate Mofetil
• Azathioprine
• Leflunomide
• Cyclophosphamide
• Others
• Antiarrhythmic Drugs
• Antimalarial Drugs
• Chloroquine
• Hydroxychloroquine
• Tumor Necrosis Factor-Alpha (Tnf-Alpha)

Inhibitors

• Adalimumab
• Infliximab
• Others

 Drugs Type

• Branded and Generic
• H.P. Acthar Gel
• Adempas
• Rayos
• Ofev
• Ara 290
• Others

Route of Administration

• Oral and Parenteral
• Intravenous
• Subcutaneous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Cardiac Sarcoidosis Market Regional Analysis/Insights

The cardiac sarcoidosis market is analyzed and market size insights and trends are provided by country, treatment, drugs type, inhibitors, route of administration, end user and distribution channel as referenced above.

The countries covered in the cardiac sarcoidosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Germany is dominating the Europe cardiac sarcoidosis market with a large number of companies operating in the market with high focus on research and innovation and API manufacturing. Furthermore, pharmaceutical industry investment has increased significantly in recent years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The cardiac sarcoidosis market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiac sarcoidosis market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiac sarcoidosis market. The data is available for historic period 2011-2021.

Competitive Landscape and Cardiac Sarcoidosis Market Share Analysis

The cardiac sarcoidosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiac sarcoidosis market.

Some of the major players operating in the cardiac sarcoidosis market are:

• Hikma Pharmaceuticals PLC (U.K.)
• Mylan N.V. (U.S.)
• Amneal Pharmaceuticals LLC. (U.S.)
• Mallinckrodt (U.K.)
• AbbVie Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Relief Therapeutics (Switzerland)
• Sandoz International GmbH (Switzerland)
• Teva Pharmaceuticals USA, INC. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• sanofi-aventis U.S. LLC (U.S.)
• Zydus Pharmaceuticals, Inc. (U.S.)
• Fresenius Kabi USA (U.S.)
• Merck & Co., Inc. (U.S.)

Research Methodology: Europe Cardiac Sarcoidosis Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

SKU-54437